Neurontin Settlement Of $430 Mil. Is High For Off-Label Case, Low For Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's $430 mil. Neurontin off-label promotion settlement is the equivalent of about nine weeks of U.S. sales of the anti-epileptic brand
You may also be interested in...
Schering-Plough Physician Payments May Be Next Target Of Federal Prosecutors
Increasing media coverage, including a CNN interview with the Boston U.S. Attorney and the Neurontin “whistleblower,” has raised the profile of allegations that Schering offered inappropriate payments to physicians to prescribe Intron-A.
Schering-Plough Physician Payments May Be Next Target Of Federal Prosecutors
Increasing media coverage, including a CNN interview with the Boston U.S. Attorney and the Neurontin “whistleblower,” has raised the profile of allegations that Schering offered inappropriate payments to physicians to prescribe Intron-A.
Pfizer Pregabalin Approved For Marketing In Europe; FDA Review Continues
The Neurontin follow-on is approved in the EU for neuropathic pain and as add-on therapy for partial seizures in patients with epilepsy. FDA's user fee deadline for pregabalin (Lyrica) is Oct. 30; Neurontin (gabapentin) generics could hit the market prior to pregabalin's approval.